Sugi Predict

Sugi Predict / Compounds / SCHEMBL7180613

SCHEMBL7180613

SCHEMBL7180613

COc1cccc(Cl)c1C(=O)c1ccccc1[PH](=O)CC(C)CC(C)(C)C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TGM2 P21980 1/20 0.38
▸ RORC P51449 1/20 0.34
▸ SMN1; SMN2 Q16637 2/20 0.34
▸ HPGD P15428 2/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ FABP4 P15090 1/20 0.34
▸ LMNA P02545 1/20 0.33
▸ XBP1 P17861 1/20 0.33
▸ CES2 O00748 1/20 0.33
▸ CES1 P23141 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ CA12 O43570 1/20 0.33
▸ CA1 P00915 1/20 0.33
▸ CA2 P00918 1/20 0.33
▸ CA7 P43166 1/20 0.33
▸ CA9 Q16790 1/20 0.33
▸ CA14 Q9ULX7 1/20 0.33
▸ CTSD P07339 1/20 0.32
▸ ITGB1 P05556 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7187534 0.92 CA12 (0.36) SMN1; SMN2HPGDL3MBTL1LMNAXBP1
SCHEMBL7189077 0.90 POLB (0.33) RORCRAB9ALMNAKMT2AITGB1
SCHEMBL7185625 0.86 RORC (0.37) RORCLMNAITGB1ITGA4POLB
SCHEMBL29364918 0.85 CA12 (0.35) HPGDXBP1CA12CA1CA2
SCHEMBL7179705 0.83 ALDH1A1 (0.35) SMN1; SMN2RAB9AL3MBTL1KMT2A
SCHEMBL7181265 0.80 ALDH1A1 (0.32) L3MBTL1KMT2A
SCHEMBL7182745 0.79 ALDH1A1 (0.41) TGM2RORCSMN1; SMN2HPGDRAB9A
SCHEMBL7182252 0.78 TGM2 (0.40) TGM2RORCSMN1; SMN2HPGDRAB9A
SCHEMBL7183921 0.77 CTSS (0.33) SMN1; SMN2HPGDLMNA
SCHEMBL7183831 0.76 HPGD (0.39) SMN1; SMN2HPGDL3MBTL1LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 — — US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 — — US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 — — US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 TGM2 3583/4885RORC 1336/4885SMN1; SMN2 2939/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 TGM2 3431/4885RORC 1254/4885SMN1; SMN2 3105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.